UBS analyst Matthew Weston upgraded Bayer (BAYRY) to Buy from Neutral with a price target of EUR 52, up from EUR 48. The firm cites the recent share pullback and the positive approval of the U.S. glyphosate case for the upgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer price target lowered to EUR 53 from EUR 55 at Morgan Stanley
- Bayer Targets Earlier Prostate Cancer Use for Darolutamide With New China Phase 2 Trial
- Bayer Earnings Call: Solid Execution, Heavy Legal Overhang
- Bayer ‘pleased’ with court’s preliminary approval of Roundup class settlement
- Midday Fly By: Stocks climb as oil prices pull back